BCR-ABL p210 for the Cepheid GeneXpert®
BCR-ABL p210 is the hallmark genetic abnormality of chronic myeloid leukemia (CML). Detecting BCR-ABL p210 is critical for confirming a CML diagnosis, guiding treatment decisions, and monitoring response to therapy, making it an essential test for patient care. Use MMQCI controls to ensure accurate results for your patients:
BCR-ABL p210 for other platforms
Our Birlinn portfolio of unassayed controls for molecular testing comprises 2 oncology quality controls for BCR-ABL p210 that have been tested and are compatible with multiple platforms, including assays on the AB Analitica, QIAGEN, and Bioclarma systems. Check out our Birlinn Oncology controls , and feel free to reach out to us to inquire about about your specific assay.
BCR-ABL p190 for the Cepheid GeneXpert®
BCR-ABL p190 is the key genetic marker in acute lymphoblastic leukemia (ALL), the most common type of leukemia in children. Testing is essential to confirm diagnosis, guide targeted treatment, and monitor therapy, helping ensure the best outcomes for patients. Achieve precise and consistent results with MMQCI controls:
NPM1 testing for the Cepheid GeneXpert®
NPM1 (Nucleophosmin 1) mutations are most commonly associated with acute myeloid leukemia (AML), particularly in adults. Molecular testing for NPM1 is important because it helps confirm diagnosis, stratify risk, guide treatment decisions, and monitor minimal residual disease, improving patient management and outcomes. Our controls make it easier to maintain accuracy in patient testing:
PML-RARA testing for the Cepheid GeneXpert®
PML-RARA is the fusion gene that defines acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML). Molecular testing for PML-RARA is essential to confirm diagnosis, guide treatment with targeted therapies, and monitor disease response, which is critical for preventing life-threatening complications. Our controls support accuracy, giving you confidence in every test:
Bladder cancer testing on the Cepheid GeneXpert®
Bladder cancer can vary in aggressiveness and treatment response. Testing for markers like CRH, IGF2, UPK1B, ANXA10, and ABL1 helps guide personalized therapy, assess prognosis, and monitor disease, supporting better outcomes for patients. MMQCI control help you deliver accurate results for every patient.